Company intelligence / Profile preview

SX Company

Yeongdeungpo-gu, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

SX Company is a South Korean investment firm and venture capital entity that specializes in the life sciences and healthcare sectors. The company is best known for its strategic investments in clinical-stage biotechnology firms, including its participation in the 2021 Series D funding round for OncoPep, a developer of therapeutic cancer vaccines. Headquartered in Seoul, SX Company operates as a bridge for capital between Asian markets and Western biopharmaceutical innovation. Its portfolio focus typically includes oncology, immunotherapeutics, and novel drug delivery platforms. The firm is often associated with other major Korean healthcare investors such as Tera Science and Kukje Pharma.

Industry: Investors

Partnerships

OncoPepTera ScienceKukje PharmaCrystalBioScience

Beyond the preview

Go deeper on SX Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SX Company.

Explore the full profile